The Claim

Rosuvastatin treatment in adults with low LDL cholesterol and elevated inflammation does not increase the risk of cancer, neuropsychiatric events, myopathy, or renal dysfunction, even among those achieving LDL-C levels below 50 mg/dL.

Source: Cardiovascular event reduction and adverse events among subjects attaining low-density lipoprotein cholesterol <50 mg/dl with rosuvastatin. The JUPITER trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin).

What the research says

Supports is higher

Support is ahead, but a single strong opposing study can change this.

Supports
59score
Challenges
0score

These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.

Cause and effect
1 study reviewed
In plain English

Taking rosuvastatin does not raise the risk of cancer, brain or nerve-related side effects, muscle damage, or kidney problems in adults with low LDL cholesterol and high inflammation, even when LDL cholesterol is lowered below 50 mg/dL.

See the scientific wording

Rosuvastatin treatment in adults with low LDL cholesterol and elevated inflammation does not increase the risk of cancer, neuropsychiatric events, myopathy, or renal dysfunction, even among those achieving LDL-C levels below 50 mg/dL, providing reassurance about the safety of aggressive lipid-lowering therapy.

Why this might work

Rosuvastatin blocks cholesterol production in the liver, which causes the liver to pull more cholesterol out of the blood. This lowers cholesterol levels in the bloodstream without activating harmful processes in other tissues. Even when cholesterol drops very low, the body does not damage muscle cells, nerve cells, kidney cells, or trigger abnormal cell growth because the drug's action is confined to the liver and does not disrupt essential functions elsewhere.

Verified mechanismbased on 1 study

What the research says

1 study

  1. Study: Cardiovascular event reduction and adverse events among subjects attaining low-density lipoprotein cholesterol <50 mg/dl with rosuvastatin. The JUPITER trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin).

    This study found that taking rosuvastatin to lower cholesterol below 50 mg/dL didn’t cause more cancer, muscle problems, memory issues, or kidney damage than taking it to a higher level — so it’s safe even when cholesterol is pushed very low.

Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies

Fit Body Science verdict — we translate health claims into clear verdicts backed by peer-reviewed research.

Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.